Meningococcal Vaccines Session

David S. Stephens, M.D.
Chair, Meningococcal Work Group

Advisory Committee on Immunization Practices
February 28, 2019
Two serogroup B meningococcal (MenB) vaccines licensed for persons aged 10—25 years in 2014 and 2015

- MenB-FHbp (Trumenba®, Pfizer):
  - Persons at increased risk for serogroup B meningococcal disease: 3-dose series administered at 0, 1-2, 6 months
  - Healthy adolescents: 2-dose series administered at 0 and 6 months

- MenB-4C (Bexsero®, GlaxoSmithKline):
  - 2-dose series administered at 0 and ≥1 month
ACIP MenB recommendations for persons at increased risk for serogroup B meningococcal disease

- In February 2015, ACIP recommended that persons aged ≥10 years at increased risk for serogroup B meningococcal disease receive a MenB primary series:
  - Persons with complement component deficiency (including complement inhibitor use)
  - Persons with functional or anatomic asplenia
  - Microbiologists routinely exposed to isolates of *Neisseria meningitidis*
  - Persons exposed during an outbreak

- These groups are also recommended to receive a quadrivalent meningococcal conjugate (MenACWY) primary dose or series.
  - Booster dose every 5 years thereafter for as long as increased risk remains.
ACIP MenB recommendations for adolescents

- In June 2015, ACIP recommended that adolescents aged 16-23 years may be vaccinated with a MenB primary series based on individual clinical decision-making (preferred age of 16-18 years).
MenB booster doses

- ACIP does not currently recommend MenB booster doses for persons at increased risk for serogroup B meningococcal disease.
  - Recommendation would be off-label; booster vaccination currently not licensed.

- Data and considerations for MenB booster doses were presented at the February, 2017 ACIP meeting.
  - ACIP requested further data to inform policy options.

- Additional data on immune persistence following a MenB primary series and immunogenicity, safety, and persistence of a MenB booster dose have been generated.
  - Manufacturers have indicated that no further data are forthcoming.
Meningococcal Vaccines Work Group Activities

- Reviewed data on persistence of the immune response following a MenB primary series and immunogenicity, persistence, and safety of a MenB booster dose.

- Formulated policy questions and evaluated quality of evidence for MenB booster doses.

- Summarized Work Group perspectives and developed potential MenB booster policy options for ACIP feedback.
Agenda

- Summary of data on the immune persistence following a MenB-FHbp primary series and immunogenicity and safety of a MenB-FHbp booster dose: Dr. Paul Balmer (Pfizer)

- Summary of data on the immune persistence following a MenB-4C primary series and immunogenicity and safety of a MenB-4C booster dose: Dr. Phil Watson (GSK)

- GRADE and Evidence to Recommendations Framework for MenB booster doses: Dr. Catherine Bozio (CDC/NCIRD)

- Work Group interpretation of data, considerations, and next steps: Dr. Sarah Mbaeyi (CDC/NCIRD)
Work Group Members

**ACIP Members**
- David Stephens (Chair)
- Kelly Moore
- Hank Bernstein
- Veronica McNally

**Ex Officio Members**
- Lucia Lee (FDA)
- Anuja Rastogi (FDA)
- Ruth Brenner (DOD)

**CDC Work Group Lead**
- Sarah Mbaeyi (CDC/NCIRD)

**Liaison Representatives**
- Nina Ahmad (AAFP)
- Oliver Baclic (NACI)
- Carol Baker (IDSA)
- Susan Even (ACHA)
- Rachel Herlihy (IAC)
- Nneka Holder (SAHM)
- Martin Luta (CSTE)
- Ruth Lynfield (AAP)
- Paul McKinney (APTR)
- William Schaffner (NFID)

**Consultants**
- Mike Brady
- Kathleen Harriman
- Mary Healy
- Cody Meissner
- Paul Offit
- Lorry Rubin
For more information, contact CDC
1-800-CDC-INFO (232-4636)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.